参考文献/References:
[1] Kirkman DL,Bohmke N,Billingsley HE,et al. Sarcopenic obesity in heart failure with preserved ejection fraction[J]. Front Endocrinol (Lausanne),2020,11:558271.
[2] Ding R. Exercise-based rehabilitation for heart failure:clinical evidence[J]. Adv Exp Med Biol,2017,1000:31-49.
[3] Huang R,Palmer SC,Cao Y,et al. Cardiac rehabilitation programs for chronic heart disease:a Bayesian network meta-analysis[J]. Can J Cardiol,2021,37(1):162-171.
[4] Nascimento CM,Ingles M,Salvador-Pascual A,et al. Sarcopenia frailty and their prevention by exercise[J]. Free Radic Biol Med,2019,132:42-49.
[5] Roh JD,Houstis N,Yu A,et al. Exercise training reverses cardiac aging phenotypes associated with heart failure with preserved ejection fraction in male mice[J]. Aging Cell,2020,19(6):e13159.
[6] Reddy Y,Rikhi A,Obokata M,et al. Quality of life in heart failure with preserved ejection fraction:importance of obesity,functional capacity,and physical inactivity[J]. Eur J Heart Fail,2020,22(6):1009-1018.
[7] Sotomi Y,Hikoso S,Nakatani D,et al. Sex differences in heart failure with preserved ejection fraction[J]. J Am Heart Assoc,2021,10(5):e018574.
[8] Matsumura K,Teranaka W,Matsumoto H,et al. Loss of skeletal muscle mass predicts cardiac death in heart failure with a preserved ejection fraction but not heart failure with a reduced ejection fraction[J]. ESC Heart Fail,2020,7(6):4100-4107.
[9] Saw EL,Ramachandran S,Valero-Mu?oz M,et al. Skeletal muscle (dys)function in heart failure with preserved ejection fraction[J]. Curr Opin Cardiol,2021,36(2):219-226.
[10] Baral N,Changezi HU,Khan MR,et al. Inspiratory muscle training in patients with heart failure with preserved ejection fraction:a meta-analysis[J]. Cureus,2020,12(12):e12260.
[11] Wintrich J,Kindermann I,Ukena C,et al. Therapeutic approaches in heart failure with preserved ejection fraction:past,present,and future[J]. Clin Res Cardiol,2020,109(9):1079-1098.
[12] Schiattarella GG,Rodolico D,Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction[J]. Cardiovasc Res,2021,117(2):423-434.
[13] Adamczak DM,Oduah MT,Kiebalo T,et al. Heart failure with preserved ejection fraction—A concise review[J]. Curr Cardiol Rep,2020,22(9):82.
[14] Paulus WJ,Tsch?pe C. A novel paradigm for heart failure with preserved ejection fraction:comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J]. J Am Coll Cardiol,2013,62(4):263-271.
[15] van Heerebeek L,Hamdani N,Falc?o-Pires I,et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction[J]. Circulation,2012,126(7):830-839.
[16] Schiattarella GG,Altamirano F,Tong D,et al. Nitrosative stress drives heart failure with preserved ejection fraction[J]. Nature,2019,568(7752):351-356.
[17] Luca M,Luca A. Oxidative stress-related endothelial damage in vascular depression and vascular cognitive impairment:beneficial effects of aerobic physical exercise[J].Oxid Med Cell Longev,2019,2019:8067045.
[18] Trigiani LJ,Hamel E. An endothelial link between the benefits of physical exercise in dementia[J]. J Cereb Blood Flow Metab,2017,37(8):2649-2664.
[19] Shah SJ,Lam C,Svedlund S,et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction:PROMIS-HFpEF[J]. Eur Heart J,2018,39(37):3439-3450.
[20] Shah SJ,Borlaug BA,Kitzman DW,et al. Research priorities for heart failure with preserved ejection fraction:National Heart,Lung,and Blood Institute Working Group Summary[J]. Circulation,2020,141(12):1001-1026.
[21] Hage C,Svedlund S,Saraste A,et al. Association of coronary microvascular dysfunction with heart failure hospitalizations and mortality in heart failure with preserved ejection fraction:a follow-up in the PROMIS-HFpEF study[J]. J Card Fail,2020,26(11):1016-1021.
[22] Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction[J]. Rev Cardiovasc Med. 2020,21(4):531-540.
[23] Kyselovi? J,Leddy JJ. Cardiac fibrosis:the beneficial effects of exercise in cardiac fibrosis[J]. Adv Exp Med Biol,2017,999:257-268.
[24] Yang HL,Hsieh PL,Hung CH,et al. Early moderate intensity aerobic exercise intervention prevents doxorubicin-caused cardiac dysfunction through inhibition of cardiac fibrosis and inflammation[J]. Cancers (Basel),2020,12(5):1102.
[25] Cohen JB,Schrauben SJ,Zhao L,et al. Clinical phenogroups in heart?failure with preserved ejection fraction:detailed phenotypes,prognosis,and response to?spironolactone[J]. JACC Heart Fail,2020,8(3):172-184.
[26] Fukuta H,Goto T,Wakami K,et al.. Effects of exercise training on cardiac function,exercise capacity,and quality of life in heart failure with preserved ejection fraction:a meta-analysis of randomized controlled trials[J]. Heart Fail Rev,2019,24(4):535-547.
[27] Pagan LU,Damatto RL,Gomes MJ,et al. Low-intensity aerobic exercise improves cardiac remodelling of adult spontaneously hypertensive rats[J]. J Cell Mol Med,2019,23(9):6504-6507.
[28] Leggio M,Fusco A,Loreti C,et al. Effects of exercise training in heart failure with preserved ejection fraction:an updated systematic literature review[J]. Heart Fail Rev,2020,25(5):703-711.
[29] Bean G,Mou J,Pflugeisen B,et al. Exercise training in patients with heart failure with preserved ejection fraction:a community hospital pilot study[J]. J Cardiovasc Nurs,2021,36(2):124-130.
[30] Li D,Chen P,Zhu J. The effects of interval training and continuous training on cardiopulmonary fitness and exercise tolerance of patients with heart failure-a systematic review and meta-analysis[J]. Int J Environ Res Public Health,2021,18(13):6761.
[31] Donelli da Silveira A,Beust de Lima J,da Silva Piardi D,et al. High-intensity interval training is effective and superior to moderate continuous training in patients with heart failure with preserved ejection fraction:a randomized clinical trial[J]. Eur J Prev Cardiol,2020,27(16):1733-1743.
[32] Anderson L,Sharp GA,Norton RJ,et al. Home-based versus centre-based cardiac rehabilitation[J]. Cochrane Database Syst Rev,2017,6(6):CD007130.
相似文献/References:
[1]孙慧雪 郑美芳 李海 孙磊 顾翔.远程医疗应用于射血分数保留性心力衰竭的现状及进展[J].心血管病学进展,2020,(3):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
SUN Huixue,ZHENG Meifang,LI Hai,et al.Status Progress of Telemedicine in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(4):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
[2]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[3]张华胜 王钰.心脏康复治疗冠心病的临床应用进展[J].心血管病学进展,2020,(7):701.[doi:10.16806/j.cnki.issn.1004-3934.20.07.008]
ZHANG Huasheng,WANG Yu.Application of Cardiac Rehabilitation in Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2020,(4):701.[doi:10.16806/j.cnki.issn.1004-3934.20.07.008]
[4]高可 杨蕾 姚新叶 郑小璞.射血分数保留性心力衰竭动物模型的研究进展[J].心血管病学进展,2020,(8):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]
GAO Ke,YANG Lei,YAO Xinye,et al.Advances in Animal Models ofHeart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(4):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]
[5]王军力 黄渊旭.高强度间歇训练在心脏康复领域的研究进展[J].心血管病学进展,2020,(11):1126.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
in Cardiac Rehabilitation.High-intensity Interval Training[J].Advances in Cardiovascular Diseases,2020,(4):1126.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[6]刘春秋 熊双 刘剑刚 董国菊.射血分数保留性心力衰竭的诊断的研究进展[J].心血管病学进展,2021,(9):784.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
LIU Chunqiu,XIONG Shuang,LIU Jiangang,et al.Diagnosis of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(4):784.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[7]宋雨 李耘 马丽娜.老年人衰弱和射血分数保留性心力衰竭病理生理学机制的研究进展[J].心血管病学进展,2022,(1):38.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.010]
SONG Yu,LI Yun,MA Lina.Pathophysiological Mechanisms of Frailty and Heart Failure with Preserved Ejection Fraction in the Elderly[J].Advances in Cardiovascular Diseases,2022,(4):38.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.010]
[8]赵菲 刘永铭.抗炎类药物对射血分数保留性心力衰竭患者心外膜脂肪组织的影响[J].心血管病学进展,2022,(1):41.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
ZHAO Fei,LIU Yongming.Effects of Anti-Inflammatory Drugs on Epicardial Adipose Tissue in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(4):41.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
[9]张文珺 牛小伟 刘永铭.m6A甲基化在射血分数保留性心力衰竭中的作用的研究进展[J].心血管病学进展,2022,(1):44.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.012]
ZHANG Wenjun,NIU Xiaowei,LIU Yongming.m6A RNA Methylation in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(4):44.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.012]
[10]聂琼 吴镜.射血分数保留性心力衰竭：从机制到治疗[J].心血管病学进展,2022,(3):258.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2022.03.0170]
NIE Qiong,WU Jing.Heart Failure with Preserved Ejection Fraction:from Mechanism to Treatment[J].Advances in Cardiovascular Diseases,2022,(4):258.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2022.03.0170]